A detailed history of Ubs Asset Management Americas Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 39,838 shares of LGND stock, worth $4.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,838
Previous 45,869 13.15%
Holding current value
$4.75 Million
Previous $3.86 Million 3.26%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$82.7 - $110.11 $498,763 - $664,073
-6,031 Reduced 13.15%
39,838 $3.99 Million
Q2 2024

Aug 13, 2024

BUY
$68.53 - $87.91 $2.06 Million - $2.65 Million
30,130 Added 191.44%
45,869 $3.86 Million
Q3 2023

Nov 13, 2023

SELL
$58.86 - $72.67 $171,400 - $211,615
-2,912 Reduced 15.61%
15,739 $943,000
Q1 2023

May 15, 2023

BUY
$65.67 - $77.08 $67,640 - $79,392
1,030 Added 5.85%
18,651 $1.37 Million
Q2 2022

Aug 12, 2022

SELL
$74.52 - $117.06 $307,693 - $483,340
-4,129 Reduced 18.98%
17,621 $1.57 Million
Q1 2022

May 16, 2022

BUY
$94.99 - $151.56 $119,402 - $190,510
1,257 Added 6.13%
21,750 $2.45 Million
Q4 2021

Feb 14, 2022

SELL
$127.69 - $165.85 $123,603 - $160,542
-968 Reduced 4.51%
20,493 $3.17 Million
Q3 2021

Nov 15, 2021

SELL
$102.33 - $144.73 $55,155 - $78,009
-539 Reduced 2.45%
21,461 $2.99 Million
Q2 2021

Aug 16, 2021

BUY
$113.03 - $155.64 $454,154 - $625,361
4,018 Added 22.34%
22,000 $2.89 Million
Q1 2021

May 14, 2021

BUY
$99.52 - $215.83 $54,736 - $118,706
550 Added 3.16%
17,982 $2.74 Million
Q4 2020

Mar 01, 2021

SELL
$80.55 - $106.05 $5.69 Million - $7.49 Million
-70,633 Reduced 80.21%
17,432 $1.73 Million
Q3 2020

Nov 13, 2020

BUY
$89.56 - $126.72 $6.21 Million - $8.78 Million
69,311 Added 369.58%
88,065 $8.39 Million
Q2 2020

Aug 14, 2020

BUY
$68.28 - $123.65 $546 - $989
8 Added 0.04%
18,754 $2.1 Million
Q1 2020

May 15, 2020

SELL
$63.37 - $107.88 $3.3 Million - $5.63 Million
-52,143 Reduced 73.56%
18,746 $1.36 Million
Q4 2019

Feb 14, 2020

SELL
$96.94 - $113.59 $334,346 - $391,771
-3,449 Reduced 4.64%
70,889 $7.39 Million
Q3 2019

Nov 14, 2019

BUY
$86.25 - $120.16 $32,688 - $45,540
379 Added 0.51%
74,338 $7.4 Million
Q2 2019

Aug 15, 2019

SELL
$107.38 - $129.34 $120,265 - $144,860
-1,120 Reduced 1.49%
73,959 $0
Q1 2019

May 14, 2019

BUY
$105.93 - $142.47 $158,259 - $212,850
1,494 Added 2.03%
75,079 $0
Q4 2018

Feb 13, 2019

SELL
$128.36 - $272.13 $572,999 - $1.21 Million
-4,464 Reduced 5.72%
73,585 $9.99 Million
Q3 2018

Nov 14, 2018

SELL
$211.18 - $274.49 $5.77 Million - $7.51 Million
-27,345 Reduced 25.95%
78,049 $0
Q2 2018

Aug 14, 2018

SELL
$150.77 - $207.98 $1.09 Million - $1.5 Million
-7,236 Reduced 6.42%
105,394 $0
Q1 2018

May 14, 2018

SELL
$138.63 - $182.62 $259,515 - $341,864
-1,872 Reduced 1.63%
112,630 $0
Q4 2017

Feb 09, 2018

BUY
$128.36 - $147.04 $4,235 - $4,852
33 Added 0.03%
114,502 $0
Q3 2017

Nov 13, 2017

BUY
$120.91 - $137.94 $13.8 Million - $15.8 Million
114,469
114,469 $0

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.01B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.